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Abstract: Obstructive sleep apnea syndrome (OSAS) and chronic obstructive pulmonary disease 
(COPD) are two diseases that often coexist within an individual. This coexistence is known as 
overlap syndrome and is the result of chance rather than a pathophysiological link. Although 
there are claims of a very high incidence of OSAS in COPD patients, recent studies report 
that it is similar to the general population. Overlap patients present sleep-disordered breathing 
associated to upper and lower airway obstruction and a reduction in respiratory drive. These 
patients present unique characteristics, which set them apart from either COPD or OSAS patients. 
COPD and OSAS are independent risk factors for cardiovascular events and their coexistence 
in overlap syndrome probably increases this risk. The mechanisms underlying cardiovascular 
risk are still unclear, but may involve systemic inﬂ  ammation, endothelial dysfunction, and tonic 
elevation of sympathetic neural activity. The treatment of choice for overlap syndrome in stable 
patients is CPAP with supplemental oxygen for correction of upper airway obstructive episodes 
and hypoxemia during sleep.
Keywords: chronic obstructive pulmonary disease, obstructive sleep apnea syndrome, overlap 
syndrome, sleep, cardiovascular disease
Introduction
Chronic obstructive pulmonary disease (COPD) is a condition of progressive deterioration 
of the respiratory system characterized by obstruction of pulmonary airways and 
decreased airﬂ  ow. The airﬂ  ow limitation is usually progressive and associated to an 
abnormal inﬂ  ammatory response of the lungs to noxious particles or gases, primarily 
caused by cigarette smoking (Celli and MacNee 2004).
COPD consists of two disorders; chronic bronchitis and emphysema. The diagnosis 
of chronic bronchitis applies to patients who have a chronic productive cough for at 
least three months of the year in two or more successive years. On the other hand, 
emphysema is a pathological diagnosis describing permanent abnormal enlargement of 
the airspaces distal to the terminal bronchioles, accompanied by destruction of alveolar 
walls. Most patients have elements of both chronic bronchitis and emphysema in 
varying degrees, but some may have one without the other (Clausen 1990). Although 
mainly affecting the lungs, it also produces other signiﬁ  cant systemic consequences, 
including skeletal muscle dysfunction, nutritional abnormalities and weight loss, 
cardiovascular and nervous system abnormalities, as well as osteoskeletal effects 
(Andreassen and Vestbo 2003; Agusti 2005).
COPD is a major global epidemic affecting 5%–15% of all adults in industrialized 
countries (Pauwels et al 2001), normally presenting after the age of 50. Incidence increases 
with age, such that 50% of smokers over the age of 65 years are affected (Louw et al 
1996). Using a variety of guides, Linberg and colleagues (2005) reported a prevalence 
of COPD between 7.6% and 12.2%. In a multicenter epidemiological study carried out 
in Spain, COPD was found in 15.8% of men and 5.5% of women (Peña et al 2000).International Journal of COPD 2008:3(4) 672
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COPD is a major cause of morbidity, mortality, and 
disability in the United States. An estimated 10 million adults 
in this country were diagnosed with COPD in the year 2000 
(Lindstrom et al 2002). It is becoming more common, and 
accounts for signiﬁ  cant and increasing utilization of health 
care resources (Faulkner and Hilleman 2003; Ramsey and 
Sullivan 2003).
Obstructive sleep apnea syndrome (OSAS) is a common 
disorder characterized by recurrent upper airway collapse 
during sleep (Young et al 1993). The inspiratory efforts to 
overcome occlusion lead to arousal, sleep fragmentation, and 
oxyhemoglobin desaturation (Deegan and McNicholas 1995). 
Though clinically recognized for more than two decades 
(Gastaut et al 1965; Lugaresi et al 1972; Guilleminault 1985), 
general awareness of OSAS has been slow to develop. In a 
middle-aged population, Young and colleagues (1993) found 
that 2% of women and 4% of men presented OSAS. In our 
community, there is an OSAS prevalence of 3.4% in men, 
3% in women (Duran et al 2001), and 6.8% among subjects 
50–70 years of age (Zamarron et al 1999).
OSAS sometimes coexists with COPD. Flenley (1985) 
called this combination ‘‘overlap syndrome.” We analyze 
the epidemiology, pathophysiology, and clinical features as 
well as therapy for overlap syndrome.
Effects of sleep on ventilation
Human sleep can be divided into two patterns, nonrapid eye 
movement sleep (NREM) and rapid eye movement sleep 
(REM), each with distinctive physiological characteristics. 
The four stages of NREM sleep are categorized by the 
frequency and amplitude of the electroencephalography 
(EEG), the presence of sleep spindles and K complexes and 
electro-oculogram and electromyogram ﬁ  ndings. REM sleep 
is characterized by bursts of rapid eye movement, muscle 
atonia and shallow and irregular breathing. REM sleep is 
subdivided into two periods: tonic and phasic. Longer REM 
periods occur mainly during the last part of nocturnal sleep.
Sleep has profound effects on ventilation (Douglas et al 
1982a), which are partly attributable to a slight decrease in 
metabolic rate (Douglas 1985; White et al 1985). In fact, the 
respiratory system is challenged by sleep, and for patients 
debilitated by respiratory disease, the conditions imposed 
may become excessive and lead to failure. Furthermore, when 
respiratory failure is already present during wakefulness, the 
situation is even more serious during sleep.
We will only brieﬂ  y summarize the main effects of sleep 
on ventilation, as comprehensive descriptions already exist 
(Phillipson 1978; Krimsky and Leiter 2005).
Breathing responses are distinctly different during REM 
and NREM sleep. There is a signiﬁ  cant reduction in minute 
ventilation, especially during REM sleep, as a result of 
decreased tidal volume not being fully compensated by an 
increase in respiratory frequency (Becker et al 1999). The 
consequence is a worsening of arterial blood gases with a 
signiﬁ  cant reduction in partial pressure of oxygen in arterial 
blood (PaO2) and an increase in partial pressure of carbon 
dioxide in arterial blood (PaCO2) (Calverley et al 1982). 
During NREM sleep, gas exchange becomes altered with 
a decrease is PaO2 (Muller et al 1980), but not as much as 
during REM sleep.
Compared to wakefulness, ventilatory response to hyper-
capnia and hypoxia is diminished during NREM sleep and 
further depressed during REM sleep (Douglas et al 1982b; 
Douglas 1985). The ventilatory and arousal responses to 
hypercapnia are much more robust than for hypoxia, with 
only slight changes in PaCO2 causing recognizable alterations 
of minute ventilation (Morrell et al 1995).
Decreased muscle tone during sleep increases respiratory 
resistance and the inability to compensate these changes 
probably contributes to reduced responses (Wiegand et al 
1991). During NREM sleep, the phasic electromyographic 
activity of genioglossus and geniohyoid muscles is 
well-maintained (Basner et al 1991), but tonic activity of 
upper airway dilators decreases (Wiegand et al 1990; Tangel 
et al 1992). During REM sleep, hypotonia of postural muscles, 
including intercostals muscles and other accessory respiratory 
muscles, occurs (Millman et al 1988; Wiegand 1990), and 
upper airway resistance increases (Ballard et al 1995).
Lung volume is also reduced during sleep and this is 
manifested by a reduction in the functional residual capacity 
(FRC) during NREM sleep (Hudgel and Devadatta 1984). 
Several factors, reduction in lung compliance and reduced 
respiratory muscle tone, have been suggested as potential causal 
factors in the reduction in FRC (Bryan and Muller 1980; Ballard 
et al 1990). It has been hypothesized that reduced FRC during 
sleep may induce the closure of airways within the regular 
breath, causing a ventilation–perfusion mismatch, contributing 
to the small but yet signiﬁ  cant changes in arterial saturation 
seen especially during REM sleep (Block et al 1979).
Effects of sleep on ventilation 
in COPD patients
The control of breathing in patients with COPD follows 
the same basic principles as in normal subjects; however, 
these patients present lower feedback response during sleep. 
A decrease in oxygen saturation during sleep may appear International Journal of COPD 2008:3(4) 673
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in normal subjects, as well as COPD patients; however, 
in the latter it has a much greater effects on arterial blood 
gases due to the different position of initial PaO2 on the O2 
dissociation curve.
Nocturnal desaturation in COPD patients presents speciﬁ  c 
characteristics (Table 1). It mainly takes place at the end 
of the night during REM sleep (Catterall et al 1985) and 
events may vary considerably from one night to the next, 
especially in patients with moderate-to-severe COPD (Lewis 
et al 2003). In addition, these desaturations are signiﬁ  cantly 
related to daytime hypoxemia and hypercarbia (Mulloy and 
McNicholas 1996); the more pronounced daytime hypoxemia 
and hypercapnia, the more severe nocturnal hypoxemia 
(Flenley 1985). Furthermore, COPD patients may require 
direct assessment of nocturnal desaturation by oximetry, 
because the degree of hypoxemia during sleep cannot be 
predicted from measurement of arterial oxygen saturation 
in individual awake patients.
The main mechanism causing nocturnal desaturations in 
COPD patients is periodic hypoventilation, which, in turn, is 
believed to be the result of decreased activity in intercostals 
muscles and blunted chemical respiratory drive (Tatsumi 
et al 1986; Heijdra et al 1995). This is especially pronounced 
in patients with hyperinflated lung (Berthon-Jones and 
Sullivan 1984). Another cause of nocturnal desaturations is 
the worsening of ventilation perfusion mismatching which 
is related to a decreased functional residual capacity and the 
dissociation between diaphragmatic and intercostals activity 
during REM sleep.
Effects of sleep on ventilation 
in OSAS patients
During apneas caused by obstruction, the collapsed pharynx 
impedes airﬂ  ow in spite of continued effort to breathe. This 
causes progressive asphyxia, which increasingly stimulates 
breathing efforts against the collapsed airway, typically 
until the person is awakened (Wiegand and Zwillich 1994). 
Various factors, ranging from upper airway anatomy to 
central respiratory control mechanisms, interact to produce 
the clinical syndrome of OSAS. The primary defect is 
probably an anatomically small or collapsible pharyngeal 
airway, in combination with a sleep-induced fall in upper 
airway muscle activity (Liistro 2002; Fogel et al 2004). One 
or more of these variables, which conspire to cause upper 
airway obstruction (Hudgel 1992; Badr 1999), may affect 
any given OSAS patient.
Some studies have shown that ventilatory control is less 
stable in patients with OSAS, (Hudgel et al 1998; Younes et al 
2001), while other authors claim that ventilatory instability 
alone is not sufﬁ  cient to produce periodic breathing (Wellman 
et al 2004). Upper airway resistance in OSAS appears to be 
inﬂ  uenced by the intensity of the central respiratory drive 
(Series et al 1989).
Abnormal hypoxic and hypercapnic respiratory drive has 
also been reported in hypercapnic OSAS patients, in contrast 
to normal hypoxic and hypercapnic respiratory drive in 
eucapnic patients (Garay et al 1981; Soto Campos et al 1996). 
The role of this reduction in chemical drives is still under 
discussion. It is not clear whether it is an inherited abnormality 
in ventilatory control (El Bayadi et al 1990; Redline et al 
1997), or secondary to sleep apnea as suggested by the 
improvement in ventilatory response to CO2 in hypercapnic 
OSAS patients after CPAP therapy (Berthon-Jones and 
Sullivan 1987; Lin 1994). Lin studied six patients with hyper-
capnic OSAS and 24 patients with eucapnic OSAS. Both the 
slope and baseline level of ventilatory response and mouth 
occlusion pressure improved signiﬁ  cantly in hypercapnic 
patients after two weeks of CPAP therapy (Lin 1994).
Overlap syndrome
Physiological consequences
Clinical evidence suggests that the majority of patients with 
OSAS are eucapnic during wakefulness, and that detection 
of daytime hypercapnia attests to mechanical impairment 
of the respiratory system due to obesity and/or COPD 
(Guilleminault et al 1976; Leech et al 1987).
Overlap syndrome predisposes to daytime hypercapnia 
and hypoxemia independently of lung function (Chaouat 
et al 1997). Nocturnal desaturation severity is related to a 
speciﬁ  c entity within the wide spectrum of sleep-disordered 
breathing and the severity of COPD.
It is known that overlap patients present more nocturnal 
desaturation than patients with either OSAS or COPD 
alone (Chaouat et al 1995; Sanders et al 2003). Sanders and 
colleagues (2003) examined the degree to which COPD and 
Table 1 COPD desaturation characteristics
Occurs mainly during REM sleep
Presents considerable variability in nocturnal desaturation from night to 
night
Statistically relationships exist between nocturnal desaturation and daytime 
hypoxemia and hypercarbia
Nocturnal desaturarion cannot be predicted from awake measurement of 
arterial oxygen saturation in individual patients
Abbreviations: COPD, chronic obstructive pulmonary disease; REM, rapid eye 
movement sleep.International Journal of COPD 2008:3(4) 674
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OSAS independently and jointly contribute to desaturation 
during sleep. After adjusting for confounding factors, the 
odds ratio for nocturnal oxyhemoglobin desaturation was 
considerably increased in OSAS patients. Bednarek and 
colleagues (2005) compared polysomnographic variables 
between overlap syndrome and OSAS subjects. The overlap 
syndrome group had lower mean arterial blood saturation and 
spent more time in desaturation than the OSAS group. Radwan 
and colleagues (1995) compared the breathing pattern and CO2 
response in 11 obese male overlap syndrome patients, 20 obese 
male OSAS patients with normal lung function, and 13 healthy 
nonobese controls. Overlap patients had a higher breathing 
frequency and lower tidal volume than OSAS patients. The 
OSAS group presented similar values to controls in ventilatory 
response to CO2 and occlusion pressure responses. This author 
concludes that overlap patients with hypercapnia have both 
blunted ventilatory responses and mouth occlusion pressure 
responses to CO2 (Radwan et al 1995) and that ventilatory 
response may be disturbed by lung mechanics and gas 
exchange. In subjects with chronic hypercapnia, there is an 
increased blood bicarbonate concentration, which may inhibit 
CO2 sensitivity and decreases mouth occlusion pressure 
response (Radwan et al 1995). Other authors have postulated 
that hyperinﬂ  ation of the lung may also decrease mouth 
occlusion pressure response (Erbland et al 1990).
In patients with overlap syndrome, sleep disordered 
breathing is associated with upper and lower airway 
obstruction and a reduction in respiratory drive. Respiratory 
muscles may also fatigue which is related to the mechanical 
disadvantage of chest wall hyperinﬂ  ation. Moreover, there 
is also a reduction in functional residual capacity which is 
related to supine posture and sleep state, and a ventilation 
perfusion mismatch (Figure 1).
Pulmonary hemodynamics
Pulmonary hemodynamic studies during sleep in COPD 
patients have been scarce probably because its invasive 
nature is not compatible with normal sleep (Weitzenblum 
and Chaouat 2004).
Alveolar hypoxia is the most important mechanism 
leading to pulmonary arterial vasoconstriction and pulmonary 
hypertension (Bonsignore et al 1994) and COPD is frequently 
complicated by the development of pulmonary hypertension, 
which is associated with increased morbidity and mortality 
(Chaouat et al 2005; Wright et al 2005).
OSAS patients may also present sustained pulmonary 
hypertension (Sanner et al 1997; Sajkov et al 1999; Bady et al 
2000), and the risk increases considerably if it is associated 
with COPD, obesity or both (Bradley 1992; Laks et al 1995; 
Chaouat et al 1996).
In a group of patients with overlap syndrome, Chaouat and 
colleagues (1995) found that the main determinants of pulmonary 
hypertension were daytime arterial blood gases and FEV1. In a 
study by Hawrylkiewicz and colleagues (2004), pulmonary 
hypertension was found in 13.6% of OSAS patients (related to 
disease severity and obesity) and in 80% of overlap patients.
Epidemiology
Overlap syndrome has a prevalence of 14% among patients 
with mild COPD (Chaouat et al 1995) and 11% among 
patients with OSAS (Sanders et al 2003).The prevalence of 
overlap syndrome is very different depending on the deﬁ  nition 
used. Some of the apparent discrepancies between studies can 
be explained by differences in selection criteria, population 
characteristics and design (Table 2). In early studies, a high 
prevalence of OSAS was found in individuals with COPD. 
Guilleminault and colleagues (1980) studied 26 COPD 
patients while sleeping and found that 92% of all abnormal 
respiratory events during sleep contained an obstructive 
component. Chaouat and colleagues (1995) prospectively 
investigated 265 OSAS patients and reported that 11% had an 
obstructive spirographic pattern. Resta and colleagues (2000) 
retrospectively evaluated data from 213 consecutive patients 
referred to the Sleep Laboratory, and found that 16% had 
overlap syndrome. De Miguel and colleagues (2002) found 
a 28.5% prevalence of overlap in a group of patients referred 
to the hospital. However, this high prevalence could well 
be due to a selection bias. Nevertheless, a very large study 
including 5,954 participants done in conjunction with the 
Sleep Heart Health Study, did not ﬁ  nd signiﬁ  cant differences 
in the prevalence of OSAS among COPD subjects (14.0%) 
and those without COPD (18.6%) (Sanders et al 2003). In 
the study by Zamarron and colleagues (2003) of 300 patients 
referred for clinical suspicion of OSAS, 15.4% of patients 
were classiﬁ  ed as overlap. More recently, Bednarek and 
colleagues (2005) studied 356 males and 320 females and 
found overlap syndrome in 9.2% of the OSAS population, 
while O’Brien and Whitman (2005) found overlap syndrome 
in 11.9% of COPD patients.
OSAS, COPD, and cardiovascular risk
Systemic inﬂ  ammation is increasingly being recognized as a 
risk factor for a number of different complications including 
atherosclerosis (Ross 1999) and is a well-established factor in 
the pathogenesis of cardiovascular disease (CVD) (Hansson 
2005). There is growing recognition that COPD is a systemic International Journal of COPD 2008:3(4) 675
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Sleep
COPD OSAS
Ventilatory instability
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respiratory
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↓Functional
residual
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Hyperinsuflated lung
Lower airway obstruction ↓Pharyngeal cross
area
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Hypoventilation
Desaturation
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mismatching
Obesity
Obstruction level Sleep disordered breathing level
Figure 1 A heuristic model of the complex associations between sleep, COPD and sleep apnea.
Abbreviations: COPD, chronic obstructive pulmonary disease; OSAS, obstructive sleep apnea syndrome.International Journal of COPD 2008:3(4) 676
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disease (Agusti et al 2003; Yende et al 2006) with multiple 
effects on end-organs including organs in the cardiovascular 
system (Camilli et al 1991; Sin and Man 2003). The 
pathophysiology of how COPD increases cardiovascular 
risk is largely unknown. Several studies have shown that 
reduced lung function is associated with an increase in a 
variety of systemic inﬂ  ammatory markers (Schols et al 
1999; Takabatake et al 2000; Godoy et al 2003). Gan and 
colleagues (2004) conducted a systematic review of studies 
involving the relationship between COPD, forced expiratory 
volume in one second (FEV1), and levels of various systemic 
inﬂ  ammatory markers. Compared to healthy controls, COPD 
patients were found to have significantly raised levels 
of C-reactive protein (CRP), ﬁ  brinogen, leucocytes, and 
tumor necrosis factor-alpha (TNF-α). All of which indicate 
persistent systemic inﬂ  ammation. This ﬁ  nding may explain, 
at least in part, the high prevalence of systemic complications 
(including cardiovascular diseases) among patients with 
COPD (Gan et al 2004).
C-reactive protein is an important serum marker of 
inﬂ  ammation and an independent predictor of cardiovascular 
disease (Rutter et al 2004; Ridker et al 2004). CRP is 
increased in COPD patients and may be a systemic marker 
of the inﬂ  ammatory process (Broekhuizen et al 2006; Man 
et al 2006; Pinto-Plata et al 2006).
A number of epidemiological studies have shown that 
OSAS is associated to cardiovascular morbidity (Nieto et al 
2000; Peker et al 2002; Becker et al 2003; Marin et al 2005). 
In this disease, intense local and systemic inﬂ  ammation 
occurs. These patients present elevated inflammatory 
mediators such as TNF-α and interleukin-6 (Liu et al 2000; 
Carpagnano et al 2002; Imagawa et al 2004; Goldbart et al 
2006), leptin (Ip et al 2000; Shimizu et al 2002; Harsch et al 
2003; Ozturk et al 2003; Barcelo et al 2005), and adhesion 
molecules (Ohga et al 1999; Chin et al 2000; El-Solh et al 
2002; Dyugovskaya et al 2002; Zamarron-Sanz et al 2006). 
The levels of these mediators improve with CPAP treatment 
(Hatipoglu and Rubinstein 2003; Minoguchi et al 2004).
As in COPD, patients with OSAS present high levels of 
CRP, which are related to disease severity (Shamsuzzaman 
et al 2002; Yokoe et al 2003; Kokturk et al 2005; Zouaoui 
et al 2006).
Endothelial dysfunction is considered an indicator of 
myocardial or vascular dysfunction before the emergence of 
clinical signs of overt cardiovascular disease (Celermajer et al 
1992). A number of studies involving OSAS patients indicate 
an associated endothelial dysfunction (Nieto et al 2004; Oﬂ  az 
et al 2006; Lattimore et al 2006) which improved after CPAP 
treatment (Ip et al 2004). Few studied, however, have focused 
on the relation between endothelial dysfunction and COPD. 
Cella and colleagues (2001) evaluated a variety of plasma 
markers of endothelial dysfunction in 14 COPD patients, ﬁ  nding 
altered level of tissue factor pathway inhibitor and selectins.
Furthermore, there is evidence of a perturbed neurohumoral 
regulatory system in COPD patients (Francis et al 1993; 
Andreas et al 2005) and OSAS patients (Somers et al 1988; 
Cortelli et al 1994).
Clinical characteristics
The most common symptoms of OSAS patients include 
chronic loud snoring, excessive daytime sleepiness, 
personality changes, and deterioration of quality of life 
(Zamarron et al 1998; Redline and Strohl 1998; Pichel et al 
2004). COPD patients, on the other hand, may present cough, 
sputum production, and/or dyspnea (Celli and Mcnee 2004). 
Nevertheless, overlap patients present unique characteristics, 
which set them apart from either COPD or OSAS patients.
A number of studies compare the clinical characteristics 
of overlap patients to those of OSAS-only patients. Chaouat 
and colleagues (1995) found that, compared to the OSAS-
only group, the overlap population tended to be older, with 
more common hypoxemia and hypercapnia, higher mean 
Table 2 Prevalence of overlap syndrome in COPD and OSAS patients
Authors Number of patients Sample Group Prevalence
Chaouat 265 Sleep Laboratory OSAS 11%
Resta 213 Sleep Laboratory OSAS 13.6%
De Miguel 193 Sleep Laboratory OSAS 28.5%
Sanders 1132 General population COPD 14%
Zamarrón 300 Sleep Laboratory OSAS 15.4%
Bednarek 676 General population OSAS 9.2%
O’Brien 120 Sleep Laboratory OSAS 11.9%
Abbreviations: COPD, chronic obstructive pulmonary disease; OSAS, obstructive sleep apnea syndrome.International Journal of COPD 2008:3(4) 677
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pulmonary artery pressures, but similar body mass index 
(BMI). O’Brien and Whitman (2005) found that overlap 
patients were older and less obese. Resta and colleagues 
(2002) showed that overlap patients had higher PaCO2, as 
well as similar apnea–hypoapnea index (AHI). This author 
developed a model for predicting PaCO2 in overlap patients 
based on PaO2, FEV1, and weight. However, overlap patients 
need not be distinctive in all variables. For example, studies by 
Radwan and colleagues (1995) and Zamarron and colleagues 
(2003) found no signiﬁ  cant differences in OSAS severity, 
mean arterial oxygen saturation during sleep, and BMI.
Special notice should be taken of Kessler’s (1996) 
suggestion that in OSAS patients exhibiting permanent 
pulmonary hypertension, bronchial obstruction is generally 
not severe and the level of hypoxemia and hypercapnia is 
modest. Therefore, chronic airway obstruction in these patients 
may be asymptomatic, making it necessary to systematically 
perform pulmonary function tests in all patients diagnosed 
with OSAS by polysomnography (Kessler et al 1996).
Quality of sleep
There is evidence that insomnia and other sleep problems 
are increased in patients with COPD (Cormick et al 1986). 
Particularly in elderly COPD patients, sleep quality is 
decreased in the form of morning tiredness and early 
awakenings (Bellia et al 2003). In addition, data from sleep 
studies has shown marked increases in stage changes, frequent 
arousals and awakenings, long sleep latency, and reduced 
sleep efﬁ  ciency (Fleetham et al 1982, Brezinova et al 1982). 
All these sleep disturbance are likely to have multifactorial 
origins. Symptoms or comorbid conditions such as nocturnal 
cough, wheezing, depression, drugs, sedentary lifestyle, and 
shortness of breath may also contribute (Weitzenblum and 
Chaouat 2004).
In OSAS patients, one of the most incapacitating 
symptoms is excessive daytime somnolence, which results 
from disrupted sleep or nighttime oxygen desaturation 
(Colt et al 1991; Seneviratne and Puvanendran 2004). 
Nevertheless, COPD patients did not have any signiﬁ  cant 
daytime sleepiness, despite feeling somewhat tired (Orr et al 
1990; Saaresranta et al 2005).
Sanders and colleagues (2003) have observed that COPD-
only patients had minimally perturbed sleep. No signiﬁ  cant 
differences were observed in sleep structure with respect to 
FEV1. Redline and colleagues (2004), in a community-based 
study, showed that sleep structure variables did not change 
in subjects with a history of lung disease. In addition, they 
found that sleep stage distributions varied in accordance 
with AHI level.
Poor-quality sleep may also be associated to hypoxemia 
and increased superﬁ  cial sleep (Sandek et al 1999).
Diagnostic procedures
The diagnosis of OSAS should be based on clinical ﬁ  ndings 
and conﬁ  rmed by a full-night polysomnography, which has 
traditionally been regarded as the gold standard for diagnosis 
(Deegan and McNicholas 1996; Flemons 2002; Kushida et al 
2005). However, alternatives that are less expensive and time 
consuming are increasingly becoming popular (Flemons et al 
2004; Whitelaw et al 2005) (Figure 2).
OXYGEN SATURATION
HEART RATE
30
100
250
30
Figure 2 Simultaneous recording of nocturnal oximetry and heart rate in a patient with COPD.
Abbreviation: COPD, chronic obstructive pulmonary disease.International Journal of COPD 2008:3(4) 678
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With respect to COPD, clinical assessment should include 
questions about sleep quality and possible co-existing OSAS. 
Polysomnography studies are not indicated in COPD except 
in special circumstances which include a clinical suspicion of 
OSAS (hypersomnolence), nocturnal hypoxemia complications 
unexplained by waking arterial oxygen levels, and pulmonary 
hypertension that is out of proportion to the severity of pulmonary 
function derangement (Douglas and Flenley 1990).
Treatment
All patients with OSAS should be counseled about the potential 
beneﬁ  ts of therapy and the risks of going without therapy. 
Furthermore, they should be advised of the importance of 
avoiding factors that increase the severity of upper-airway 
obstruction such as sleep deprivation, the use of alcohol, 
hypnotic agents, and increased weight (Loube et al 1994; 
Haynes 2005). Although CPAP therapy is a well-established, 
widely used treatment, it is not suitable for all patients (Patel 
et al 2003; Marshall et al 2006; Giles et al 2006).
Conventional O2 therapy is prescribed to stable COPD 
patients who exhibit marked and persistent hypoxemia. This 
therapy is sufﬁ  cient for correcting even severe nocturnal 
desaturation and has favorable effects on the observed 
hypoxemia related peaks of pulmonary hypertension 
(Fletcher and Levin 1984). Some authors report that oxygen 
therapy improves the quality of sleep by shortening latency 
to sleep, increasing REM sleep as well as stages 3 and 4, 
and by decreasing number of arousals (Goldstein et al 1984, 
Calverley et al 1982). However, discrepant results exists 
(Fleetham et al 1982; McKeon et al 1989), which may be 
due to differences in the severities of daytime and nighttime 
hypoxemia, as well as study design.
In some patients, particularly those with hypercapnia, 
higher oxygen ﬂ  ows may induce further carbon dioxide 
retention with resultant morning headache and confusion. 
However, if there is a marked worsening in hypercapnia with 
oxygen therapy, noninvasive nocturnal ventilation (NIPPV) 
may be added. Although the precise mechanisms are not yet 
clear, NIPPV could improve gas exchange in COPD patients 
by resting the respiratory muscles, resetting the respiratory 
centers (Elliott et al 1991) and improving respiratory 
mechanics (Simonds et al 1989). Nevertheless, there are 
conﬂ  icting results regarding the utility of this treatment in 
long-term COPD, particularly during sleep (Wijkstra et al 
2003; Ambrosino and Strambi 2004).
Additional treatment options include theophylline, 
ipratropium bromide tiotropium (Man et al 1996; Martin 
et al 1999; McNicholas et al 2004).
Certain drugs should be administered with caution. 
Hypnotics, for example, can adversely affect respiration and 
gas exchange in patients with COPD by decreasing upper 
airway muscle tone and blunting the respiratory drive (Steens 
et al 1993). It is also advisable for COPD patients to avoid 
alcohol ingestion before sleep because it has been shown to 
worsen hypoxemia (Easton et al 1987) or lead to hypercapnic 
respiratory failure (Chan et al 1990).
The coexistence of OSAS and COPD deﬁ  nes a group 
of special risk patients. In these overlap patients, waking 
and sleep-related hypoxemia and hypoxemic cardiovascular 
consequences are more marked than in OSAS-only patients.
CPAP has been shown to acutely improve overnight 
oxygenation in patients with overlap syndrome. In fact, CPAP 
with supplemental oxygen for correction of upper airway 
obstructive episodes and hypoxemia during sleep is the 
treatment of choice for these patients (Sampol et al 1996).
Few studies exist on the long-term effect of CPAP 
in overlap syndrome. De Miguel and colleagues (2002) 
evaluated the effects of CPAP therapy on lung function in 
patients with overlap syndrome over two consecutive years. 
After six months of CPAP therapy, there were statistically 
signiﬁ  cant increases in PaO2, FEV1, and forced vital capacity 
(FVC). Response of overlap syndrome patients to CPAP 
therapy was superior in the hypercapnic group, particularly 
in relation to improvement of arterial blood gases.
Mansﬁ  eld and Naughton (1999) evaluated the effects of 
CPAP on lung function in patients with overlap. Fourteen 
patients were studied, ten of whom were able to tolerate 
CPAP for at least three months. Improvement was found 
in gas exchange and FEV1 associated with a decrease in 
hospitalizations.
CPAP treatment may have other potentially beneﬁ  ts. 
As COPD is an inﬂ  ammatory airways disorder, it may be 
that OSAS acts as an inﬂ  ammatory stimulus. Thus, the 
improvement in OSAS resulting from the application of 
CPAP may, in turn, lead to an improvement in the coexistent 
COPD. Nevertheless, further study is still needed.
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